RxDoctor Payments Data

Sabari Arcot, OD

Optometrist · St. Louis, MONPI 1982288163

Payments from drug & device makers

$2,585in general payments, 2019–2025

Across 64 payments — averaging $40.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$490
  • Johnson & Johnson Vision Care, Inc.$435
  • Coopervision Inc.$360
  • Sun Pharmaceutical Industries Inc.$260
  • Bausch & Lomb Americas Inc.$233
  • AbbVie$166
  • plus $641 from 10 others

What the payments were for

  • Consulting fees$70027%
  • Speaking & faculty fees$35014%
  • Food & beverage$1,45656%
  • Gifts$793%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,585 in reported general payments places this provider in the 80th percentile of 1,030 optometrist providers in Missouri.

See all optometrist providers in Missouri

Medicare billing

Part B allowed, 2024
$155,754
Medicare patients
610
Services billed
2,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine30$20,890
LumiganBimatoprost34$17,367
Fluorometholone116$8,009
Cyclosporine11$7,408
Prednisolone Acetate170$5,699
SimbrinzaBrinzolamide/Brimonidine Tart20$4,761
Alphagan PBrimonidine Tartrate17$4,228
MoxifloxacinMoxifloxacin Hcl170$3,141
CombiganBrimonidine Tartrate/Timolol14$3,004
TafluprostTafluprost/Pf23$2,903
Dorzolamide-TimololDorzolamide/Timolol/Pf17$2,259
Latanoprost233$2,087
Loteprednol Etabonate15$1,592
Ketorolac Tromethamine86$1,230
Brimonidine Tartrate45$962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$166$45,48895 claims
AlconSimbrinza$490$4,76120 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$154$1,59215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,030 optometrist providers in Missouri.

Other optometrist in St. Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →